SABCS 2019 - Elisabetta Munzone - SABC Highlights

Elisabetta Munzone giving her personal SABC 2019 Highlights

SABCS 2019 - JoaquiÌn Gavilá - SABC Highlights (EN)

JoaquiÌn Gavilá giving his personal SABC 2019 Highlights (EN)

SABCS 2019 - JoaquiÌn Gavilá - SABC Highlights (ES)

JoaquiÌn Gavilá giving his personal SABC 2019 Highlights (ES)

SABCS 2019 - Mario Campone - SABC Highlights

Mario Campone giving his personal SABC 2019 Highlights

SABCS 2019 - Natalija Plavetic - SABC Highlights

Natalija Plavetic giving her personal SABC 2019 Highlights

SABCS 2019 - Patrick Neven - SABC Highlights

Patrick Neven giving his personal SABC 2019 Highlights

SABCS 2019 - Rachel Layman - SABC Highlights

Rachel Layman giving her personal SABC 2019 Highlights

SABCS 2019 - 01 - Francois Duhoux - SABC Highlights

Francois Duhoux giving his personal SABC 2019 Highlights

SABCS 2019 - 03 - Michele De Laurentiis - SABC Highlights

Michele De Laurentiis -giving his personal SABC 2019 Highlights

SABCS 2019 - Claudio Zamagni - SABC Highlights

Claudio Zamagni giving his personal SABC 2019 Highlights

SABCS 2019 - Natalija Plavetic; Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study

SABCS 2019 - Rachel Layman; PD7-09 A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC)....

Rachel Layman is commenting on the poster: PD7-09 A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)